Vitamin D receptor genetic polymorphisms are associated with PSA level, gleason score and prostate cancer risk in african-american men

Anticancer Research

Volumn 35, Issue 3, 2015, Pages 1549-1558

  Jingwi, Emmanuel Y ^a   Abbas, Muneer ^b,c   Ricks Santi, Luisel ^d   Winchester, Danyelle ^e   Beyene, Desta ^a,b   Day, Agnes ^a   Naab, Tammey J ^b   Kassim, Olakunle O ^b   Dunston, Georgia M ^b,c   Copeland, Robert L ^f   Kanaan, Yasmine M ^a,b  

^a HOWARD UNIVERSITY CANCER CENTER   (United States)

^b Department of Microbiology ^*  (Ireland)

^c National Human Genome Center   (United States)

^d HAMPTON UNIVERSITY   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f HOWARD UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

African American; Clinical phenotype; Prostate cancer; SNP; Vitamin D receptor

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; VITAMIN D RECEPTOR; CALCITRIOL RECEPTOR;

ADULT; AFRICAN AMERICAN; ALLELE; ARTICLE; CANCER RISK; CODOMINANCE; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; CANCER GRADING; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK;

AFRICAN AMERICANS; AGED; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, CALCITRIOL; RISK;

EID: 84924970944     PISSN: 02507005     EISSN: 17917530     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Jemal A, Center MM, DeSantis C and Ward EM: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 19: 1893-1907, 2010.
2. American Cancer Society, Cancer Facts and Statistics 2014.
3. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
4. Gurel B, Iwata T, Koh CM, Yegnasubramanian S, Nelson WG and De Marzo AM: Molecular alterations in prostate cancer as diagnostic, prognostic, and therapeutic targets. Adv Anat Pathol 15: 319-331, 2008.
5. Kidd LR, Coulibaly A, Templeton TM, Chen W, Long LO, Mason T, Bonilla C, Akereyeni F, Freeman V, Isaacs W, Ahaghotu C and Kittles RA: Germline BCL-2 sequence variants and inherited predisposition to prostate cancer. Prostate Cancer Prostatic Dis 9: 284-292, 2006.
6. Bai Y, Yu Y, Yu B, Ge J, Ji J, Lu H, Wei J, Weng Z, Tao Z and Lu J: Association of vitamin D receptor polymorphisms with the risk of prostate cancer in the Han population of Southern China. BMC Med Genet 10: 125-132, 2009.
7. Quinn M and Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries. BJU Int 90: 174-184, 2002.
8. Hamasaki T, Inatomi H, Katoh T, Aono H, Ikuyama T, Muratani T and Matsumoto T: N-acetyltransferase-2 gene polymorphism as a possible biomarker for prostate cancer in Japanese men. Int J Urol 10: 167-173, 2003.
9. Feldman D: Androgen and vitamin D receptor gene polymorphisms: the long and short of prostate cancer risk. J Natl Cancer Inst 89: 109-111, 1997.
10. Blutt SE and Weigel NL: Vitamin D and prostate cancer. Proc Soc Exp Biol Med 221: 89-98, 1999.
11. Miller GJ: Vitamin D and prostate cancer: biologic interactions and clinical potentials. Cancer Metastasis Rev 17: 353-360, 1998.
12. Hendrickson WK, Flavin R, Kasperzyk JL, Fiorentino M, Fang F, Lis R, Fiore C, Penney K, Ma J, Kantoff PW, Stampfer MJ, Loda M, Mucci LA and Giovannucci EL: Vitamin D receptor protein expression in tumor tissue and prostate cancer progression. J Clin Oncol 29: 2378-2385, 2011.
13. Giovannucci E: Vitamin D status and cancer incidence and mortality. Adv Exp Med Biol 624: 31-42, 2008.
14. Colston K and elsh J: Vitamin D and breast cancer. Feldman D, Glorieux F, Pike J, Stanford C, editors. Vitamin D. II, pp 1663-1677, 2005. Elsevier Academic Press.
15. Miyamoto K, Kesterson RA, Yamamoto H, Taketani Y, Nishiwaki E, Tatsumi S, Inoue Y, Morita K, Takeda E and Pike JW: Structural organization of the human vitamin D receptor chromosomal gene and its promoter. Mol Endocrinol 11: 1165-1179, 1997.
16. Crofts LA, Hancock MS, Morrison NA and Eisman JA: Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. Proc Natl Acad Sci U.S.A. 95: 10529-10534, 1998.
17. National Center for Biotechnology Information (NCBI), dbSNP. 2014.
18. McKay JD, McCullough ML, Ziegler RG. Kraft P, Saltzman BS, Riboli E, Barricarte A, Berg CD, Bergland G, Bingham S, Brustad M, Bueno-de-Mesquita HB, Burdette L, Buring J, Calle EE, Chanock SJ, Clavel-Chapelon F, Cox DG. Dossus L, Feigelson HS, Haiman CA, Hankinson SE, Hoover RN, Hunter DJ, Husing A, Kaaks R, Kolonel LN, Le Marchand L, Linseisen J, McCarty CA, Overvad K, Panico S, Purdue MP, Stram DO, Stevens VL, Trichopoulos D, Willett WC, Yuenger J and Thun MJ: Vitamin D receptor polymorphisms and breast cancer risk: results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. Cancer Epidemiol Biomarkers Prev 18: 297-305, 2009.
19. Hamasaki T, Inatomi H, Matsumoto T and Katoh T: Association of vitamin D receptor gene polymorphism with prostate cancer. Nihon Rinsho 60 Suppl 11: 465-468, 2002.
20. Liu JH, Li HW, Wang JQ, Li M, Xin DQ, Na X, Zhang M, Ye SY and Na YQ: Vitamin D receptor gene Bsm I polymorphism and the susceptibility to prostate cancer in northern Chinese Han population. Zhonghua Nan Ke Xue 9: 413-416, 2003.
21. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D and Peehl DM: Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomarkers Prev 12: 23-27, 2003.
22. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY and Feldman D: The vitamin D receptor gene start codon poly-morphism: a functional analysis of FokI variants. J Bone Miner Res 13: 1691-1699, 1998.
23. Arai H, Miyamoto KI, Yoshida M, Yamamoto H, Taketani Y, Morita K, Kubota M, Yoshida S, Ikeda M, Watabe F, Kanemasa Y and Takeda E: The polymorphism in the caudal-related homeodomain protein Cdx-2 binding element in the human vitamin D receptor gene. J Bone Miner Res 16: 1256-1264, 2001.
24. Holick CN, Stanford JL, Kwon EM, Ostrander EA, Nejentsev S and Peters U: Comprehensive association analysis of the vitamin D pathway genes, VDR, CYP27B1, and CYP24A1, in prostate cancer. Cancer Epidemiol Biomarkers Prev 16: 1990-1999, 2007.
25. Hayes VM, Severi G, Eggleton SA, Padilla EJ, Southey MC, Sutherland RL, Hopper JL and Giles GG: The E211 G>A androgen receptor polymorphism is associated with a decreased risk of metastatic prostate cancer and androgenetic alopecia. Cancer Epidemiol Biomarkers Prev 14: 993-996, 2005.
26. Xu Y, He B, Pan Y, Deng Q, Sun H, Li R, Gao T, Song G and Wang S: Systematic review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Tumour Biology 35: 4153-4169, 2014.
27. Zhang Q and Shan Y: Genetic polymorphisms of vitamin D receptor and the risk of prostate cancer: a meta-analysis. J BUON 18: 961-969, 2013.
28. Guo Y, Shi Z, Liu J, Lei N, Chen Q and Tang Y: Meta-analysis of the relation between the VDR gene TaqIpolymorphism and genetic susceptibility to prostate cancer in Asian populations. Asian Pacific Journal of Cancer Prevention 13: 4441-4444, 2012.
29. Ntais C, Polycarpou A and Tsatsoulis A: Molecular epide-miology of prostate cancer: androgens and polymorphisms in androgen-related genes. Eur J Endocrinol 149: 469-477, 2003.
30. Ntais C, Polycarpou A and Ioannidis JP: Vitamin D receptor gene polymorphisms and risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 12: 1395-1402, 2003.
31. Berndt SI, Dodson JL, Huang WY and Nicodemus KK: A systematic review of vitamin D receptor gene polymorphisms and prostate cancer risk. J Urol 175: 1613-1623, 2006.
32. Guo Z, Wen J, Kan Q, Huang S, Liu X, Sun N and Li Z: Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21, 756 subjects. Tumour Biology 34: 3189-3200, 2013.
33. Sole X, Guino E, Valls J, Iniesta R and Moreno V: SNPStats: a web tool for the analysis of association studies. Bioinformatics 22: 1928-1929, 2006.
34. Oakley-Girvan I, Feldman D, Eccleshall TR, Gallagher RP, Wu AH, Kolonel LN, Halpern J, Balise RR, West DW, Paffenbarger RS Jr and Whittemore AS: Risk of early-onset prostate cancer in relation to germ line polymorphisms of the vitamin D receptor. Cancer Epidemiol Biomarkers Prev 13: 1325-1330, 2004.
35. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT and Pearson JD: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 277: 1445-1451, 1997.
36. Chen L, Davey SG, Evans DM, Cox A, Lawlor DA, Donovan J, Yuan W, Day IN, Martin RM, Lane A, Rodriguez S, Davis M, Zuccolo L, Collin SM, Hamdy F, Neal D and Lewis SJ: Genetic variants in the vitamin d receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomarkers Prev 18: 2874-2881, 2009.
37. Steuber T, Erbersdobler A, Graefen M, Haese A, Huland H and Karakiewicz PI: Comparative assessment of the 1992 and 2002 pathologic T3 substages for the prediction of biochemical recur-rence after radical prostatectomy. Cancer 106: 775-782, 2006.
38. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN and Eisman JA: Prediction of bone density from vitamin D receptor alleles. Nature 367: 284-287, 1994.
39. Morrison NA, Yeoman R, Kelly PJ and Eisman JA: Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteo-calcin. Proc Natl Acad Sci USA 89: 6665-6669, 1992.
40. Ingles SA, Ross RK, Yu MC, Irvine RA, La PG, Haile RW and Coetzee GA: Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J Natl Cancer Inst 89: 166-170, 1997.
41. Ogunkolade WB, Boucher BJ, Bustin SA, Burrin JM, Noonan K and Mannan N: Vitamin D metabolism in peripheral blood mononuclear cells is influenced by chewing "betel nut" (Areca catechu) and vitamin D status. J Clin Endocrinol Metab 91: 2612-2617, 2006.
42. Holt SK, Kwon EM, Peters U, Ostrander EA and Stanford JL: Vitamin D pathway gene variants and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 18: 1929-1933, 2009.
43. Schaid DJ: Evaluating associations of haplotypes with traits. Genet Epidemiol 27: 348-364, 2004.
44. Hayes VM, Severi G, Padilla EJ, Eggleton SA, Southey MC, Sutherland RL, Hopper JL and Giles GG: Genetic variants in the vitamin D receptor gene and prostate cancer risk. Cancer Epidemiol Biomarkers Prev 14: 997-999, 2005.
45. Baker AR, McDonnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, Pike JW, Shine J and O'Malley BW: Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 85: 3294-3298, 1988.
46. Koren R: Vitamin D receptor defects: the story of hereditary resistance to vitamin D. Pediatr Endocrinol Rev 3 (3): 470-475, 2006.
47. Belandia B and Parker MG: Nuclear receptors: a rendezvous for chromatin remodeling factors. Cell 114: 277-280, 2003.
48. Kitagawa H, Fujiki R, Yoshimura K, Mezaki Y, Uematsu Y, Matsui D, Ogawa S, Unno K, Okubo M, Tokita A, Nakagawa T, Ito T, Ishimi Y, Nagasawa H, Matsumoto T, Yanagisawa J and Kato S: The chromatin-remodeling complex WINAC targets a nuclear receptor to promoters and is impaired in Williams syndrome. Cell 113: 905-917, 2003.
49. McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ and O'Malley BW: Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69: 3-12, 1999.
50. McKenna NJ, Lanz RB and O'Malley BW: Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321-344, 1999.
51. McKenna NJ and O'Malley BW: Minireview: nuclear receptor coactivators-an update. Endocrinology 143: 2461-2465, 2002.
52. McKenna NJ and O'Malley BW: Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108: 465-474, 2002.